Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 18,832 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $55.40, for a total value of $1,043,292.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Clay B. Siegall also recently made the following trade(s):

  • On Friday, November 10th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The shares were sold at an average price of $58.00, for a total value of $1,092,256.00.

Shares of Seattle Genetics, Inc. (NASDAQ SGEN) traded up $1.10 during trading hours on Wednesday, hitting $55.71. The stock had a trading volume of 1,320,665 shares, compared to its average volume of 974,472. Seattle Genetics, Inc. has a one year low of $45.31 and a one year high of $71.32.

Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.23. Seattle Genetics had a negative return on equity of 32.41% and a negative net margin of 26.53%. The company had revenue of $135.29 million for the quarter, compared to analyst estimates of $112.76 million. During the same quarter last year, the firm earned ($0.23) EPS. Seattle Genetics’s revenue for the quarter was up 27.3% compared to the same quarter last year. research analysts expect that Seattle Genetics, Inc. will post -0.93 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in shares of Seattle Genetics by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 4,824 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 299 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of Seattle Genetics by 6.8% during the 2nd quarter. Prudential Financial Inc. now owns 6,291 shares of the biotechnology company’s stock worth $325,000 after purchasing an additional 400 shares in the last quarter. Tredje AP fonden grew its holdings in shares of Seattle Genetics by 3.7% during the 2nd quarter. Tredje AP fonden now owns 15,470 shares of the biotechnology company’s stock worth $800,000 after purchasing an additional 550 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Seattle Genetics by 1.1% during the 2nd quarter. Alliancebernstein L.P. now owns 57,241 shares of the biotechnology company’s stock worth $2,962,000 after purchasing an additional 603 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of Seattle Genetics by 0.5% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 168,023 shares of the biotechnology company’s stock worth $8,694,000 after purchasing an additional 777 shares in the last quarter. 98.94% of the stock is currently owned by institutional investors.

A number of research analysts have recently commented on SGEN shares. Cann started coverage on Seattle Genetics in a report on Wednesday, November 8th. They set a “hold” rating on the stock. Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price on shares of Seattle Genetics in a report on Monday, October 23rd. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $64.00 target price on shares of Seattle Genetics in a report on Friday, October 6th. TheStreet raised Seattle Genetics from a “d” rating to a “c” rating in a report on Thursday, November 16th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $53.00 target price on shares of Seattle Genetics in a report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $63.76.

WARNING: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/13/seattle-genetics-inc-sgen-insider-sells-1043292-80-in-stock.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.